The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

Skin cancer advanced clinical practitioners ensure continuity of care for patients with malignant melanoma and other advanced ...

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Two years after Neil Armstrong walked on the Moon, US president Richard Nixon declared a new frontier in American scientific ...

shows that blocking MARCO in combination with a type of immunotherapy known as anti-CTLA4 therapy, significantly enhances tumor regression in melanoma, the deadliest form of skin cancer.

The study randomly assigned 42 patients (one would later withdraw consent) to three immunotherapy treatment arms: nivolumab alone, nivolumab plus ipilimumab and nivolumab plus relatlimab.

Panitumumab plus ipilimumab and nivolumab signaled complete or partial response ... Despite the small sample size, the efficacy readout still supports further evaluation of [immunotherapy] ...

In this study of 36 patients with advanced HPV-negative HNSCC, researchers tested a regimen of three cycles of neoadjuvant chemotherapy combined with an immunotherapy drug, nivolumab, followed by ...

Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data The article by ...